Clinical trials
Bipolar Disorder I or II clinical trials
Below are recruiting bipolar disorder i or ii clinical trials, each written for real people, not researchers. We’re tracking 2,351 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06863506RecruitingPhase 2
Study of Befotertinib for non-small cell lung cancer with uncommon EGFR mutations
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
Hangzhou, ZhejiangAges 18 years+ - NCT07329322RecruitingPhase 2
Drug combo before surgery for EGFR-mutated lung cancer
This trial tests a combination of two targeted drugs (sacituzumab tirumotecan and osimertinib) before surgery for people with a specific type of lung cancer (EGFR-mutated). The goal is to see if the drugs can shrink the tumor enough to improve surgery results.
BeijingAges 18–75 - NCT07331155RecruitingPhase 2
LBL-024 combo for advanced esophageal cancer
This trial tests a new drug combination for advanced solid tumors, specifically esophageal cancer. It may help people whose cancer has not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06863584RecruitingPhase 2
SBRT and lenalidomide for solitary plasmacytoma
This trial tests combining a focused, high-dose radiation treatment (SBRT) with the drug lenalidomide for people with a single plasma cell tumor (solitary plasmacytoma). The goal is to see if this combination works better than radiation alone.
Hangzhou, ZhejiangAges 18–80 - NCT07331558Recruiting
Virtual reality rehab for heart surgery recovery
This study tests if virtual reality exercises can improve your heart and lung fitness after coronary artery bypass surgery. If you still feel short of breath, this might help you recover better.
Lahore, Punjab ProvinceAges 30–60 - NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07333079Recruiting
Rehabilitation with biofeedback for stroke recovery
This study tests if adding biofeedback to standard rehabilitation improves hand and arm function after a stroke. Biofeedback uses sensors to show you how your muscles are working, helping you regain movement.
RzeszówAges 45–80 - NCT07325630RecruitingPhase 2
Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07325734Recruiting
Written therapy for teens with complex PTSD
This study tests if a guided writing therapy helps adolescents with complex PTSD. It is designed for teens who have difficulties after trauma and can read and write well enough to do the writing exercises.
Fuyang, AnhuiAges 10–18 - NCT07330037RecruitingPhase 2
TIL plus immunotherapy for NSCLC without complete response after chemoimmunotherapy
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 17–75 - NCT07328854RecruitingPhase 3
Lower versus standard radiation in stage II nasopharyngeal cancer
This trial compares a lower dose of radiation (40.2 Gy) to the standard dose (49.2 Gy) for patients with stage II nasopharyngeal carcinoma that has shrunk after initial chemoimmunotherapy. The goal is to see if the lower dose works just as well while potentially causing fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT07320105RecruitingPhase 4
Radiation after surgery for lung cancer that spread to lymph nodes
This trial tests if giving radiation after surgery can help people with non-small cell lung cancer that has spread to multiple lymph nodes in the chest. It may offer a treatment option for those who have not had chemotherapy or immunotherapy before.
Fuzhou, FujianAges 18–75 - NCT07318103RecruitingPhase 2
Study of HRS-9057 for fluid retention in heart failure
This trial tests an investigational drug, HRS-9057, in people hospitalized with heart failure who still have fluid buildup despite taking standard diuretics. The goal is to see if HRS-9057 helps remove excess fluid better than current treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06869863RecruitingPhase 1/Phase 2
Study of MediReg® for severe male infertility
This study tests an experimental medicine called MediReg® for men with severe infertility who have not been able to conceive. It aims to see if the drug is safe and can improve sperm quality, possibly offering a new option for men who have not had success with other treatments.
Moscow, MoscowAges 21–60 - NCT07321769Recruiting
3D eye modeling study for lens and eye structure disorders
This trial uses advanced imaging to create 3D models of the eye in people with lens problems, eye structure anomalies, trauma, or cataract complications. It aims to improve diagnosis and treatment planning for these conditions.
Hangzhou, ZhejiangAges Any age - NCT07316582Enrolling by invitationPhase 4
Melatonin gel for gum disease treatment
This trial tests a new gel made with melatonin and platelet-rich fibrin to treat gum disease. It may help reduce pocket depth and improve gum health without surgery.
New CairoAges 20–60 - NCT07318831RecruitingPhase 2
Combination drug therapy for relapsed neuroblastoma
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
Tianjin, Tianjin MunicipalityAges birth–18 years - NCT06560112RecruitingPhase 2
Combination therapy trial for recurrent ovarian cancer
This trial tests two experimental drugs, AK104 and AK112, for ovarian cancer that has come back after standard platinum chemotherapy. It may be an option if your cancer is a high-grade type and you have had prior treatment.
ShanghaiAges 18 years+ - NCT06728280Recruiting
DTMS for teens with depression: safety and effectiveness
This trial tests if a new type of brain stimulation called DTMS can safely help adolescents with major depression. It may be an option if you have tried other treatments and are looking for a non-medication approach.
Taiyuan, ShanxiAges 11–23 - NCT05470088Recruiting
MRI study of people with autism, their relatives, and controls
This study uses an MRI scan to better understand brain differences in people with autism spectrum disorder (ASD), and compares them with their relatives and people without ASD. It mainly helps researchers connect brain findings with genetics and background health information.
Gif-sur-YvetteAges 2 years+ - NCT06089577RecruitingPhase 4
Cangrelor for heart blood flow during planned stent procedure
This trial tests if cangrelor, a fast-acting blood thinner, can prevent small vessel damage during a planned stent placement in patients with stable chest pain. It may help improve blood flow to the heart muscle.
FerraraAges 18 years+ - NCT07313059Recruiting
Clonal hematopoiesis study for people 55+
This study looks at a condition called clonal hematopoiesis (CH), where some blood cells have changes that may affect their health. It aims to prevent, treat, and better understand CH. You may qualify if you are 55 or older and have low blood counts that persist over time.
Canberra, Australian Capital TerritoryAges 55 years+ - NCT07314294RecruitingPhase 2
Study of EMB-01 for advanced left-sided colorectal cancer
This trial tests a new drug, EMB-01, in people with advanced left-sided colorectal cancer that has spread or cannot be removed. It may help if standard treatments have stopped working or caused side effects.
BeijingAges 18 years+
Hear when a new Bipolar Disorder I or II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bipolar disorder i or ii?
- Yes. Clin2 currently lists 2,351 recruiting bipolar disorder i or ii studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bipolar disorder i or ii trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bipolar disorder i or ii trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.